EPO and chronic kidney disease: Treatment with daprodustat showed a dose-dependent increase in EPO and Hgb levels. The mean change of Hgb increased by 1.0 g/dL in CKD stages 3–5 and >0.5 g/dL in CKD-5D. These results were also associated with a decrease in hepcidin levels and an increase in the TIBC.